9 Meters Biopharma Gross Profit

9 Meters Biopharma posts a gross profit of $0 as of March 2023. In the prior-year period, the figure was $0. That is below the Technology sector average of $2.1T. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, 9 Meters Biopharma's gross profit was $0. The latest reading is $0 (period ending March 2023). Use the history and growth charts on this page for a longer lookback.

For Technology stocks, a gross profit near $2.1T is typical. 9 Meters Biopharma's $0 is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of 9 Meters Biopharma's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for NMTR's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $2.1T), and (3) consistency with growth and profitability. This page covers the first two; 9 Meters Biopharma's other metric pages and overview cover the third.